MAPK/ERK pathway: Difference between revisions
No edit summary |
No edit summary |
||
| Line 53: | Line 53: | ||
*The first drug licensed to act on this pathway is [[sorafenib]] — a Raf kinase inhibitor. | *The first drug licensed to act on this pathway is [[sorafenib]] — a Raf kinase inhibitor. | ||
*'''Dabrafenib''' ''e.g.'' [[4xv2]] - B-Raf Kinase V600E oncogenic mutant in complex with Dabrafenib. | *'''Dabrafenib''' ''e.g.'' [[4xv2]] - B-Raf Kinase V600E oncogenic mutant in complex with Dabrafenib. | ||
*B-Raf Kinase Inhibitor Zelboraf - Generic: '''Vemurafenib''' (Formerly: PLX-4032), see [[B-RAF with PLX4032]]. | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||